Press releases
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
- Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
More ▼
Key statistics
On Monday, Marinus Pharmaceuticals (MRNS*:MEX) closed at 124.00, 0.00% above its 52-week low of 124.00, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 124.00 |
Low | 124.00 |
Bid | -- |
Offer | -- |
Previous close | 124.00 |
Average volume | -- |
---|---|
Shares outstanding | 54.93m |
Free float | 54.31m |
P/E (TTM) | -- |
Market cap | 66.47m USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 20 minutes, as of Apr 15 2024 18:38 BST.
More ▼